Celgene (NASDAQ: CELG) reported Q3 EPS of $1.23, $0.02 better than the analyst estimate of $1.21. Revenue for the quarter came in at $2.33 billion versus the consensus estimate of $2.4 billion.

"Our strong third quarter performance and acceleration of key drivers create significant momentum in our business, further advancing us toward our 2020 targets,” said Bob Hugin, Chairman and Chief Executive Officer of Celgene Corporation. “The continued progress of our clinical pipeline and important strategic collaborations have us well-positioned for long-term growth.”

015 Guidance for REVLIMID® and ABRAXANE® Updated

• Total net product sales are expected to be in the range of $9.0 billion to $9.5 billion (consensus is $9.29B)
• REVLIMID® net sales are expected to be approximately $5.8 billion, an increase from the previous range of $5.6 billion to $5.7 billion
• ABRAXANE® net sales are expected to be in the range of $950 million to $1.0 billion, a decrease from the previous range of $1.0 billion to $1.25 billion
• Adjusted 2015 operating margin remains unchanged at approximately 52 percent; GAAP operating margin is expected to be approximately 25.2 percent, lowered from approximately 36.4 percent
• Adjusted diluted EPS is expected to be in the range of $4.75 to $4.85 (consensus is$4.82)
• GAAP diluted EPS is expected to be in the range of $2.02 to $2.24, a decrease from the previous range of $2.17 to $2.46

For earnings history and earnings-related data on Celgene (CELG) click here.